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Background: Cyclooxygenase (COX) and epidermal growth factor receptor (EGFR) activities promote progression of
colorectal cancer. Combined treatment against these targets has not been more effective than single treatments
alone. Therefore, our aim was to analyze relationships between COX and EGFR in peroperative colorectal tumor
biopsies.
Method: Tumor and colon mucosa tissue were collected at primary intended curative operations in patients
according to well-recognized statistical distributions of tumor stages in colorectal cancer. COX-1, COX-2 and EGFR
content in tumor and colon mucosa tissue were quantified by western blot and Q-PCR.
Results: COX-2 protein appeared as two bands, one at 66 kDa in almost all tumor and mucosa samples and one at
74 kDa in 73% of the tumors and in 23% of the mucosa samples. Tumor COX-2 mRNA was not different from the
content in mucosa samples, while COX-2 protein was increased in tumor tissue (p < 0.0003). A correlation between
74 kDa COX-2 protein and COX-2 mRNA occurred in tumor tissue, with significantly increasing COX-2 mRNA across
tumor stages. EGFR mRNA content was lower in tumor tissue (p < 0.0001), while EGFR protein was similar in tumor
and mucosa samples. COX-2 and EGFR proteins showed a positive correlation in mucosa, while a negative
correlation occurred in tumor tissue. Tumor tissue with high COX-2 74 kDa protein lacked EGFR protein.
Conclusion: Our present results are compatible with the theory that COX-2 and EGFR signalling pathways are
inversely related in colorectal cancer tissue. This may explain why combinatorial clinical treatments have been
less rewarding.
Keywords: COX-2, EGFR, Colorectal cancer, mRNA, Western blotBackground
Several studies have reported and concluded that inhib-
ition of COX may decrease the risk for colorectal cancer
(CRC) and subsequent death [1-5], while other studies
have indicated favorable anti-EGFR treatment of CRC; a
treatment which is already in clinical use [6,7]. COX and
EGFR are thus suggestive targets for combinatorial treat-
ment of CRC since both pathways involve tumor pro-
gression and are reported to show increased activities in
CRC tissue. There are also published information that
increased COX-2 expression may lead to subsequently
increased EGFR expression including cross-talk between* Correspondence: annika.gustafsson@surgery.gu.se
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy,
University of Gothenburg, Bruna Stråket 20, Gothenburg 413 45, Sweden
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reproduction in any medium, provided the orthe two signalling pathways [8]. Accordingly, combined
treatment against COX-2 and EGFR activities has been
rewarding in animal studies [9]. However, clinical trials
with dual blockade of EGFR and COX-2 in patients with
CRC have so far not improved clinical outcome com-
pared to the use of the single treatments alone [10].
Previous analyses in our laboratory indicated that tu-
mors treated with COX inhibitors, showed reduction in
COX-2 mRNA in combination with decreased expression
of EGFR in experimental tumors on mice [11]. However,
in a previous study we found unexpected discrepancies be-
tween mRNA and protein content of COX-2 in preopera-
tive colorectal tumor biopsies from patients [12]. Most
reported studies, mainly based on immunohistochemical
analysis of protein content, describe significantly increasedLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Asting et al. BMC Cancer 2013, 13:511 Page 2 of 9
http://www.biomedcentral.com/1471-2407/13/511expression of COX-2 in tumor tissues while transcript
analyses have not confirmed elevated mRNA content of
COX-2 in CRC tumor tissue [4,13,14]. It is therefore im-
portant to evaluate the relationships between mRNA and
protein content of COX and EGFR in human CRC. There-
fore, the aim of the present study was to analyze tran-
scripts of COX-1, COX-2, and EGFR in relationship to




Tumor and colon tissue samples from 30 patients were se-
lected to represent a frequently recognized statistical
distribution of tumor stages from a large biobank consist-
ing of over 2000 patients who underwent primary oper-
ation for colon carcinoma between 2002 to 2009 at Östra
Hospital, Sahlgrenska University Hospital Gothenburg
Sweden. All patients underwent surgery as the only cura-
tive treatment and none had received neoadjuvant radio-
chemotherapy, according to individual decisions and insti-
tutional indications. The group of patients consisted of
53% males and 47% females with a mean age of 76.9 years
(range 51 to 93 years) at surgery. Median survival time
was 73.6 months (range 1.7 to 108.5 months) following
surgery according to a recent update of survival (Nov
2010), where 13 patients were still alive. Tumors were
histologically classified as stadium I (5), II (10), III (10)
and IV (5) corresponding to TNM stages T1N0 (2), T2N0
(3), T2N1 (1), T3N0 (9), T3N1 (6), T3N2 (6), T4N0 (1),
T4N1 (1) and T4N2 (1). Differentiation of the tumors
were 3% high (1), 70% medium (21), and 27% low (8). This
study was approved by the board of Ethics at University of
Gothenburg (365-05). Accordingly, all patients partici-
pated with informed consent.
Tumor and mucosa tissue material
Tumor and mucosa tissue samples were collected down
to the serosa level at primary operation, snap frozen in
liquid nitrogen and stored in−80°C until analysis. Certi-
fied pathologists staged all tumors. Normal colon tissue
was collected at a minimum of 10 cm away from the ap-
parent tumor tissue. Tumor localization was right sided
in 73% (22) of the cases and 27% (8) left sided.
Western blot
50-100 mg of frozen colon mucosa and tumor tissue
were thawed and homogenized with a rotor-stator
homogenizer in seven volumes of ice-cold RIPA buffer
(50 mM Tris pH 7.4, 150 mM NaCL, 0.1% SDS, 1%
Nonidet® P-40 Substitute (Igepal™ CA-630), 0.5% Deoxy-
cholic acid) with addition of Complete protease inhibitor
cocktail (Roche Diagnostics GmBh, Germany). Homoge-
nates were centrifuged twice at 10 000 × g, 10 min at4°C and the supernatant was collected. Total protein
concentration was determined by the Bradford method
using albumin as standard (Quick Start Bradford Protein
Assay, Bio-Rad Laboratories Inc.). 30 μg protein from
each supernatant were separated in 4-12% NuPage Bis-
Tris minigels using Mops buffer system, according to
the manufacturer’s instructions (Life technologies), and
transferred to PVDF membranes. Membranes were
blocked in 10% non-fat dry milk in Tris-buffered saline
containing 0.05% tween 20 (NFDM/TBST) for a mini-
mum of two hours. Next, membranes were incubated
over night at +4°C with antibodies (rabbit monoclonal
anti-EGFR (detects intracellular domain, immunizing
peptide aa 1185-1210), Millipore, 04-338; mouse mono-
clonal anti-EGFR (detects extracellular domain, immun-
izing peptide aa 30-198) Dako M7298; rabbit polyclonal
anti-COX2, Abcam ab15191 is known to detect one dis-
tinct band of 72-74 kDa; rabbit monoclonal anti-COX1,
Epitomics 3811-1; rabbit polyclonal anti-GAPDH, Milli-
pore Abs-16). Blots were then washed, incubated with
HRP-labelled secondary antibodies for 1 hour at room
temperature and developed using ECL Prime Western
Blotting Kit according to the manufacturer’s description
(Amersham Biosciences, UK). Signal was captured using
ChemiDoc XRS imaging system (BioRad Laboratories,
Sundbyberg, Sweden). After detection of signals, HRP
activity was inactivated by 2 × 30 min incubation in
hydrogen peroxide buffer (15% H2O2 in PBS) before
reprobing membranes with next antibody. Membranes
were cut horizontally after transfer and the lower
part were incubated with GAPDH antibodies while the
upper part of the membranes were incubated in EGFR
(extracellular) followed by COX2 or COX1 followed
by EGFR (intracellular) respectively. Quantification of
signals was carried out with Quantity One software
(Bio-Rad Laboratories AB, Sundbyberg, Sweden). One
tumor sample was used as “standard sample” and loaded
twice on each gel. The average optical density for the
“standard sample” was used to normalize signal intensity
between blots. Measured optical density is expressed as
arbitrary units relative to the standard sample. Magic-
Mark XP Western Protein Standards (Invitrogen) was
used for molecular weight approximation.
RNA extraction and cDNA synthesis
Total RNA from both tumor and mucosa samples from 30
patients was extracted with RNeasy® Fibrous Tissue Mini
kit from Qiagen according to the protocol for Total RNA
isolation from Fibrous Tissue enclosed by the manufac-
turer. A quality control measurement of RNA was per-
formed in Bioanalyzer 2100 (Agilent) with limit RIN 5.0
for further analysis. Concentration of RNA was determined
in NanoDrop® ND-1000 Spectrophotometer (NanoDrop
Technologies). One μg of RNA was used in Advantage®
Table 1 Number of patients with positive antibody
detection in Western blot analysis of mucosa and tumor
tissue
Mucosa (30) Tumor (30) p*
COX-1 30 (100%) 29 (97%) ns
COX-2 74 kDa 7 (23%) 22 (73%) <0.0001
66 kDa 30 (100%) 27 (90%) ns
EGFR Extracellular 170 kDa 22 (73%) 19 (63%) 0.01
all sizes 30 (100%) 22 (73%) ns
Intracellular 170 kDa 22 (73%) 19 (63%) 0.01
*Chi-square test.
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RNA in negative controls and samples without RT-
polymerase were run to exclude genomic contamination.
Q-PCR
Q-PCR was performed in the LightCycler 1.5 with LightCy-
cler FastStart DNA MasterPLUS SYBR Green I kit to analyze
the gene expression of COX-1, COX-2, and EGFR in tumor
and mucosa tissue samples according to standard protocol
(Roche) and with PCR conditions: activation 95°C 10 min,
denaturation 95°C 10 s, annealing 60°C 4 s and extension
72°C 5 s in 45 cycles. Primers were Hs_PTGS1_1_SG
(COX-1), Hs_PTGS2_1_SG (COX-2), and Hs_EGFR_1_SG
(EGFR, detects all transcript variants) (QuantiTect Primer
Assays, Qiagen). Two reference genes were run for each
sample GAPDH (Hs_GAPDH_1_SG, Qiagen) and 18 S
RNA (Hs_RRN18S_1_SG, Qiagen). Both reference genes
were run with QuantiFast SYBR Green PCR kit (Qiagen)
according to standard protocol and with PCR condition as
follow: activation 95°C 5 min, denaturation 95°C 10 s and
annealing 60°C 30 s in 40 cycles. The standard curve for
COX-1 had a slope at−4.069, error 0.103 and R−0.99,
COX-2 slope−3.674, error 0.07 and R−0.99, EGFR slope
−3.896, error 0.076 and R−0.99, GAPDH slope−3.388, error
0.034 and R−1.00, and 18 S RNA slope−3.470, error 0.029
and R−1.00. All samples were run in duplicate and related
to both reference genes ((GAPDH+ 18SRNA)/2). The
products were checked in the Bioanalyzer 2100 (Agilent
Technologies) according to the protocol for DNA1000 for
correct amplicon size. PCR-graded water was used as nega-
tive control in each reaction. Results were produced by the
relative standard curve method where the standard speci-
men was a colon tumor (stadium III, RIN 7.3). All samples
were diluted and confirmed to be within the range of the
standard curve.
Statistics
Results are presented as optical density (arbitrary units)
for protein content or relative gene expression per
GAPDH and 18 S RNA gene expressions as mean ±
standard error of units obtained from the LightCycler®
datafiles. The statistical testing among groups was per-
formed with parametrical tests (ANOVA, Fisher PLSD)
or Chi-square test (Microsoft Office Excel 2007). Correl-
ation analysis was performed with either simple or mul-
tiple regressions according to standard procedures in
Statview 5.0.1 (SAS Institue Inc.). P < 0.05 was regarded
statistically significant and p < 0.10 a trend to signifi-
cance in two-sided tests.
Results
Tissue protein content
COX-1 protein was detected in all tumor and mucosa
samples by western blot analyses except for one tumortissue sample without significant difference between
tumor and mucosa tissue (Table 1). The antibody against
COX-2 detected two bands, one at ~ 66 kDa and one at
74 kDa. The band at 66 kDa was detected in almost all
tumor and mucosa samples; only three tumors did not
display the 66 kDa band. The band at 74 kDa was de-
tected in 22 (73%) tumors and in 7 (23%) mucosa sam-
ples (Table 1). COX-2 protein content was significantly
higher in tumor tissue compared to mucosa tissue for
both 66 and 74 kDa (p < 0.03, p < 0.003, Table 2).
Altered protein content in relationship to tumor pro-
gression was found for the 74 kDa band accounting for
tumor stage (Table 2). The antibody against the intracel-
lular part of EGFR detected only full length protein at
170 kDa in 19 (63%) tumors and in 22 (73%) mucosa
samples. The antibody against the extracellular part of
EGFR detected full length protein at 170 kDa in 20
(67%) tumors and 26 (87%) mucosa samples. Bands at
lower molecular weight seemed to occur in samples with
low or extinguished 170 kDa protein in tumor and mu-
cosa tissue (Table 1, Figure 1A, B). EGFR protein was
not significantly different between tumor and mucosa
tissue (Figure 2).
Tissue mRNA content
Q-PCR displayed significantly reduced mRNA content
in tumor tissue for COX-1 and EGFR (all transcripts),
while COX-2 mRNA content was not significantly chan-
ged in tumor tissue compared to mucosa tissue (Table 2,
Figure 2). COX-2 mRNA content in tumor tissue dis-
played a trend to increase with tumor progression (p <
0.04, Figure 3) where a weak correlation between COX-2
mRNA and the 74 kDa COX-2 protein content was ob-
served in tumor tissue (p < 0.0001, Figure 4).
COX-EGFR
Regression analysis between COX-1 mRNA and EGFR
mRNA showed a trend to significance in tumor tissue
(p < 0.07). Correlation analyses between either total
COX-2 (~66 + 74 kDa) or the 74 kDa protein alone ver-
sus the intracellular and extracellular protein parts of
Table 2 COX-1, COX-2, and EGFR mRNAs and corresponding protein content in human colon mucosa compared to
tumor tissue
Tumor tissue ANOVA
Mucosa Stadium I Stadium II Stadium III Stadium IV Tumor vs mucosa Stage I-IV
p value p value
RNA (n) (26) (5) (8) (10) (4)
COX-1 10.45 ± 1.59 2.82 ± 0.90 3.40 ± 0.71 1.57 ± 0.34 7.04 ± 2.42 <0.0001 ns
COX-2 0.50 ± 0.21 0.27 ± 0.13 0.81 ± 0.21 1.02 ± 0.39 1.58 ± 0.68 ns ns
EGFR 13.66 ± 1.26 4.90 ± 1.40 5.28 ± 0.89 3.37 ± 0.58 7.02 ± 0.83 <0.0001 ns
Protein (n) (30) (5) (10) (10) (5)
COX-1 2.43 ± 0.19 1.97 ± 0.50 1.92 ± 0.38 2.98 ± 0.61 1.97 ± 0.50 ns ns
COX-2 total* 1.24 ± 0.10 1.53 ± 0.36 3.57 ± 0.68 2.34 ± 0.26 3.42 ± 0.70 <0.0001 I,II 0.002
I,IV 0.009
COX-2 66 kDa 1.00 ± 0.13 1.25 ± 0.33 1.63 ± 0.51 1.59 ± 0.32 1.62 ± 0.22 0.028 ns
COX-2 74 kDa 0.20 ± 0.02 0.25 ± 0.09 1.70 ± 0.68 0.70 ± 0.22 1.49 ± 0.82 0.003 I,II 0.014
II,III 0.036
EGFR extra 0.64 ± 0.06 0.91 ± 0.09 0.43 ± 0.12 0.40 ± 0.10 0.44 ± 0.15 ns I,II 0.009
I,III 0.006
I,IV 0.023
EGFR intra 0.54 ± 0.09 0.40 ± 0.19 0.14 ± 0.06 0.54 ± 0.16 0.42 ± 0.15 ns ns
Mean ± SEM, RNA: units/units ((GAPDH + 18SRNA)/2), protein arbitrary units. *COX-2 total=66 kDa + ~74 kDa protein band in WB. EGFR intra./EGFR extra. = ab
directed towards intracellular/extracellular EGFR protein.
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lationships between COX-1, total COX-2 and the extra-
cellular or intracellular parts of EGFR in mucosa tissue
(p < 0.06-0.0007). A negative correlation was seen be-
tween the 74 kDa COX-2 protein and the extra- and
intracellular parts of EGFR in tumor tissue (Figure 5).
Multiple regression analyses with intracellular EGFR
protein as dependent variable displayed a correlation to
the extracellular part of EGFR protein, total COX-2 and
COX-1 protein as well as EGFR mRNA content in
mucosa. No such relationships were observed in tumor
tissue (Table 3).
Discussion
Cyclooxygenases (COX) metabolize arachidonic acid to
prostanoids, which are involved and control several im-
portant steps of tumor progression [5]. In normal hu-
man colon tissue there are two isoforms of COX; COX-
1 is usually referred to as constitutively expressed in
most tissues and COX-2 is induced by pathological con-
ditions [4]. COX-1 has not been reported of in cancer to
the same extent as COX-2 even though several reports
indicate that COX-1 may be involved in tumor progres-
sion [15,16]. Also, our previous studies showed that
tumor gene expression changed to less aggressive bio-
logical characteristics, as indicated by decreased cell pro-
liferation, increased apoptosis and by more pronounced
expression of immune markers in the tumors, followingshort term preoperative inhibition by indomethacin with
a subsequent decline of both COX-1 and COX-2 [17,18].
Similar alterations are observed in different non-tumor
related reactions of immunity, regulation of transcription
and cell mobility following COX-inhibition.
Our results in the present study display that COX-1
mRNA was significantly higher in mucosa tissue com-
pared to tumor tissue, which may indicate reduced pro-
duction of COX-1 in tumor tissue. However, COX-1
protein contents were similar in tumor and mucosa tis-
sue. The impact of reduced COX-1 mRNA in tumor
tissue is unclear, but may be secondary to increased
COX-2 protein and activity in tumor tissue.
Similarly, COX-2 mRNA was not significantly in-
creased in tumor tissue versus mucosa tissue, which
confirms our previous results [12], although there was a
weak trend to increased COX-2 mRNA across tumor
progression. By contrast, COX-2 protein content was
significantly higher in tumor tissue in agreement with
several previous reports [13,19]. COX-2 is tightly regu-
lated and modified at several different levels in cell me-
tabolism [20,21]. Post-transcriptional modifications like
glycosylation are crucial for the activation and degrad-
ation of COX-2 [22]. COX-2 protein sequence contains
5 potential glycosylation sites where 3 are necessary for
proper protein folding; one appears to affect the COX-2
activity, while one is usually not glycosylated. After gly-
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Figure 1 Western blot gels for the two EGFR antibodies and the COX-2 antibody. A. Two bands were detected with the COX-2 antibody, at
approximately 66 kDa and 74 kDa. The antibody against the extracellular part of EGFR detected bands of different size. These bands are probably
the different isoforms of EGFR. (STD = standard protein, M = mucosa, T = tumor). B. EGFR samples were separated in a Nupage Tris-Acetate gel
for improved molecular weight separation. Molecular weight of proteins (kDa) was estimated from prestained molecular markers. Samples were
randomly selected.










































Figure 2 mRNA and protein content in mucosa and tumor
samples from the same patients. (A = units/units (GAPDH +
18SRNA)/2, B = optical density, arbitrary units). *p < 0.05.
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64 kDa following analythical electrophoresis [22-25].
Interestingly, non-glycosylated COX-2 protein (66 kDa)
was detected in all tumor and mucosa samples, while
mature COX-2 protein (74 kDa) was mainly detected in
tumor tissue. The function of the 66 kDa COX-2 is
unclear, but may represent unmature COX-2 that is to
be either activated or remain inactive in the cell. These
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COX-2 mRNA
Figure 3 Distribution of COX-2 mRNA content in tumor tissue
related to tumor stage, which displayed a trend to increased
expression with tumor progression. (p < 0.04 in regression
analysis, R 0.41).patterns of variable COX-2 proteins in tumor and mu-
cosa tissues may be highly significant but must await fur-
ther analytical evaluations. Few publications have
reported two bands of COX-2 in human tissues, while
most reports comment on only one homogenous COX-2
protein (72-74 kDa) in animal tissue, although three dis-
tinct COX-2 bands have also been reported in monkey
kidney cells [26]. Presently, it remains unclear too what
extent two COX-2 bands are mainly biologically or
methodology related.
Tumor tissue that contained increased mature and ac-
tive COX-2 (74 kDa) protein seemed to lack epidermal
growth factor receptor (EGFR) protein. In previous ani-
mal studies we found that EGFR and Kras mRNA were
significantly decreased in tumor tissue from mice treated
with unspecific COX inhibition [11]. Cross-talk between
these two signalling pathways has been suggested by
others where either COX-2 up-regulates EGFR or vice
versa. Such results were mainly achieved in animal
models or in cell culture experiments [8,9,27,28], where
inhibition of both EGFR and COX in combination
caused effective blockade of tumor growth and spread of
metastatic disease in mice [8,29]. However, clinical trials
have not displayed similar effects [10]. Accordingly, our
present results in human tumor tissue displayed that in-
creased COX-2 (74 kDa) was associated with low EGFR
and vice versa. It is thus possible that COX-2 and EGFR
signalling pathways are inversely related to each other in
most colorectal tumors. Thus, it might be that only one
pathway is highly active or that an alternative receptor
to EGFR is present and activated, for example HER-2
signalling [30]. Our results are opposite to findings by
others in a smaller group of patients [31,32]. On the
other hand, a positive correlation between COX-1 and
COX-2 (total protein content) versus EGFR protein con-
tent occurred in human mucosa tissue (Figure 5), al-
though total COX-2 protein content (66 plus 74 kDa)
may be less relevant in function, since non-glycosylated
COX-2 (66 kDa) may lack enzymatic activity.
Human EGFR is encoded by two transcripts of 10.5 kb
and 5.8 kb from a single promoter region/gene on
chromosome 7. The protein products from these two
transcripts are identical and encode the full-length recep-
tor (isoform A, 170 kDa). In addition, three alternative
transcripts of 2.4, 1.8 and 3.0 kb are derived from the
EGFR gene. These transcripts encode isoforms B (unkown
size), C (60/80 kDa), and D (90/110 kDa) respectively. All
these isoforms lack the intracellular part of EGFR and
therefore lack tyrosine kinase activity [33]. The electrophe-
ric bands we observed are probably isoforms of EGFR,
which may compete for the ligand with full-length EGFR
without giving rise to any internal signal.
EGFR plays a crucial role in cellular functions impli-
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Figure 4 Regression analyses between COX-2 mRNA and COX-2 protein content in tumor tissue, which displayed a correlation for
COX-2 mRNA and COX-2 74 kDa protein content.
B: Tumor tissue protein 































































































Figure 5 Statistically significant regression analyses of tumor and mucosa tissue: Panel A: RNA content (units/units reference genes)
and panel B and C: protein content (arbitrary units).
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Table 3 Multiple regression analyses with intracellular
EGFR protein expression as dependent factor in tumor
tissue (T) and mucosa tissue (M)













Insignificantly independent variables were COX-1 RNA, COX-2 RNA, 66 kDa
COX-2 protein and 74 kDa COX-2 protein.
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By contrast, our results displayed significantly decreased
mRNA content of EGFR transcripts in tumor tissue
compared to mucosa tissue without significant changes
at the protein levels of EGFR. The explanation to this
discrepancy is unclear, but an explanation may be obser-
vations that K-RAS mutations in tumor cells result in
constant activity of EGFR signaling pathways, which
might decrease EGFR mRNA by negative feedback due
to cross-talk between EGFR activity and K-RAS function
as observed in acquired resistance following anti-EGFR
treatment of patients [36]. Thus, different alterations in
turnover of mRNA and protein levels at either steady
state or non-steady state conditions could display as di-
vergent changes in cross-sectional evaluations on tissue
samples. A second explanation may simply be that
tumor EGFR mRNA was more susceptible to degrad-
ation by RNAse during tissue preparation compared
to mucosa. In addition, tumor intestinal location may
relate to different cell content of growth factors in tu-
mors among right and left-sided CRC tumors [35]. The
reason for a higher content of growth factors in left-
sided tumors is unknown, but may be related to distri-
butions of different cells along the large intestine. In our
study 27% of the patients had left-sided tumors and 73%
were right sided.
Overall, we found divergent alterations for mRNA
and protein content of COX-2 in tumor tissue, which
confirms our results in previous investigations [12].
These discrepancies may be due to the fact that mRNA
molecules are comparatively unstable and may be more
or less degraded during tissue handling [37]. Quantifi-
cation of mRNA content in tissue may however be avalid means to measure increased or decreased alterations
in protein production at specific conditions. Obviously,
there are several critical events in measurements of
mRNAs to define changes related to a specific receptor/
enzyme level; also, post-transcriptional modifications may
occur to various extent. The mRNA quality was rigorously
checked in all present analyses and only RNA with RNA
Integrity Number (RIN) above 5.0 were analyzed including
two reference genes to overcome RNA quality hazards.
Conclusion
In conclusion, the present study did not confirm correla-
tions between tissue mRNA levels and protein content
of COX-1 and EGFR, while a weak correlation was ob-
served between the 74 kDa COX-2 protein and COX-2
mRNA in colon cancer tissue, accounting for tumor
stage. By contrast, a negative correlation between COX-
2 and EGFR protein in tumor tissue occurred, which
was not observed in mucosa tissue from the same pa-
tients. Therefore, it is likely that COX-2 and EGFR sig-
nalling pathways are inversely related to each other in
human colorectal tumor tissue and that tumor cells need
only one of the signalling pathways for disease progres-
sion; a suggestion supported by our western blot results
where tumor tissues with high COX-2 protein (74 kDa)
content did not show EGFR protein expression at all.
This fact should explain why combinatorial treatment
with COX-inhibitors and anti-EGFR was not more ef-
fective than the single treatments alone [10].
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